drugset / Trial / NCT06223646
A Study of KQ-2003 CAR-T Cell Therapy for Patients With Relapsed or Refractory Multiple Myeloma
Non-randomizedSequentialOpen-labelTreatment
Summary
This is a multicenter, open-label, dose-escalation/expansion phase 1/2a study to evaluate the safety, tolerability, pharmacokinetic/pharmacodynamic characteristics and determine the recommended dose of KQ-2003 CAR T-cells for patients with Relapsed/Refractory Multiple Myeloma
Timeline
- Start
- 2024-01-11
- Primary completion
- 2026-03-31
- Completion
- 2026-03-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | KQ-2003 | Cell therapy | 1e+06 cells/kg | — |
| Subject | KQ-2003 | Cell therapy | 2e+06 cells/kg | — |
| Subject | KQ-2003 | Cell therapy | 3e+06 cells/kg | — |